TLR7 agonists(Punjabi University)

Pfizer has terminated a Phase I clinical trial evaluating PF-08046037 (also known as SGN-PDL1iT), an immunostimulatory antibody conjugate targeting PD-L1, as monotherapy and in combination with the anti-PD-1 antibody sasanlimab in patients with advanced solid tumors. The NCT06974734 clinical trial terminated after enrolling only eight participants across multiple planned cohorts, according to a ClinicalTrials.gov registry update verified in April 2026. No reason for the termination was disclosed. The open-label, non-randomized Phase I study enrolled adults with advanced or metastatic non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, or pancreatic ductal adenocarcinoma. The trial followed a sequential design moving through dose escalation, optimization, and expansion phases for both monotherapy and combination arms. Primary endpoints centered on safety — specifically dose-limiting toxicities within the first 21 days and adverse event incidence over the treatment period — with secondary objectives including pharmacokinetic characterization and preliminary efficacy signals such as objective response rate, duration of response, and progression-free survival assessed by RECIST v1.1. According to the ClinicalTrials.gov posting for the trial, the study was terminated “for strategic business reasons” with no safety and/or efficacy concerns cited. There has so far been no further public explanation from Pfizer for the termination. The trial ended within approximately ten months of its May 2026 start date. PF-08046037 entered clinical testing as part of Pfizer’s inherited Seagen pipeline following the company’s USD 43 billion acquisition of Seagen in 2023. The molecule’s alternate name, SGN-PDL1iT, reflects its Seagen origins. The molecule is an immune-stimulating antibody conjugate (ISAC) targeting PD-L1, designed to deliver a TLR7 agonist payload selectively to tumor-associated antigen-presenting cells. Following PD-L1 binding and internalization, the conjugate activates innate immune signaling within endosomes, promoting antigen presentation and reprogramming the tumor microenvironment toward an anti-tumor response. Preclinical studies showed targeted immune activation, reduction of suppressive macrophages, and anti-tumor activity with evidence of immune memory, supporting its rationale prior to program termination. The trial assessed PF-08046037 as monotherapy or in combination with sasanlimab, Pfizer’s subcutaneous anti-PD-1 monoclonal antibody developed under the code PF-06801591. Sasanlimab has its own separate clinical trajectory and recently demonstrated efficacy in a Phase III bladder cancer trial, establishing it as a viable standalone asset. Its pairing with PF-08046037 in this study represented an exploratory combination hypothesis — that innate immune activation via the conjugate might synergize with checkpoint blockade. The termination of NCT06974734 fits a broader pattern within Pfizer’s post-acquisition oncology pipeline. The company has discontinued several early-stage Seagen-derived programs since 2023, including assets in the ADC space where early safety or translational data did not meet internal thresholds. Pfizer is simultaneously executing a cost-reduction program targeting approximately USD 7.2 billion in net savings through 2027, with active rationalization of its research portfolio. Under that framework, early-stage programs without compelling early signals face a higher bar for continuation. The ISAC modality itself remains largely unproven in the clinic. The concept of using a tumor-targeting antibody to deliver a TLR agonist payload selectively to the tumor microenvironment is mechanistically appealing — it aims to convert immunologically cold tumors into inflamed ones without the systemic toxicity associated with systemic TLR agonist administration — but the approach carries inherent risks. Systemic immune activation, cytokine release, and off-tumor payload delivery are recognized liabilities, and the eligibility criteria for this trial reflected awareness of those risks through the exclusion of patients with prior immune-mediated toxicities of grade 3 or higher, active autoimmune disease, or significant pulmonary or neurodegenerative conditions. Pfizer has not indicated whether it intends to out-license PF-08046037 or pursue alternative development pathways for the asset. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

The European Medicines Agency has accepted a marketing authorization application for Cevira (APL-1702), a photodynamic drug-device combination product developed for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL) of the cervix. The application was filed by Asieris Pharmaceuticals, the Shanghai-based company that holds global development and commercialization rights to the product, which was originally developed by Photocure ASA of Oslo, Norway. If the EMA grants approval, Cevira would become the first non-surgical pharmacologic therapy authorized for cervical HSIL in any major market. Of note, Asieris previously made a New Drug Application for Cevira in China in May 2024. The MAA covers the use of Cevira for the treatment of HSIL — encompassing cervical intraepithelial neoplasia grades 2 and 3 (CIN 2/3) — in patients aged 18 years and older, excluding carcinoma in situ. The product is classified as a drug-device combination: it integrates hexaminolevulinate hydrochloride ointment, a photosensitizer, with a disposable cervical light applicator. The photosensitizer is applied topically to the cervix and then activated by an intracavity cold light source, producing localized cytotoxic effects intended to destroy dysplastic tissue while sparing normal cervical architecture. Photocure and Asieris have described the product as a first-in-class photodynamic therapy for this indication. Cevira’s clinical package The MAA submission is supported primarily by results from the APRICITY trial (NCT04484415), an international, multicenter, randomized, double-blind, placebo-controlled Phase III study enrolling 402 patients with histologically confirmed HSIL. The primary endpoint was proportion of patients achieving complete response at six months, defined as a composite of histological regression from HSIL to low-grade SIL (CIN 1) or normal, combined with clearance of the causative HPV genotype detected at baseline. Initiated by Asieris in November 2020, the study produced topline results in September 2023 showing that the primary endpoint was met with Cevira demonstrating statistically significant superiority over placebo. The safety profile reported in public disclosures describes Cevira as generally well tolerated, with the most common adverse events being local and mild — including vaginal discharge, pelvic discomfort, and minor bleeding. No treatment-related serious adverse events were reported. APL-1702 Cervical Treatment: Why It Matters The acceptance of this application by the EMA arrives in a therapeutic space defined almost entirely by surgical intervention. The standard of care for cervical HSIL has long relied on excisional procedures, principally loop electrosurgical excision (LEEP/LLETZ) and cold knife conization, which are effective at removing precancerous tissue but carry documented risks. These include cervical incompetence, preterm birth in subsequent pregnancies, cervical stenosis, and procedural complications. Because HSIL disproportionately affects women of reproductive age, typically between 25 and 45 years, the consequences of tissue removal extend well beyond the immediate procedure. No pharmacologic therapy has previously received regulatory authorization for HSIL in any jurisdiction. Investigational approaches have included therapeutic HPV vaccines such as VGX-3100 (Inovio Pharmaceuticals), a DNA-based vaccine targeting HPV 16/18 E6 and E7 oncoproteins, which showed activity in Phase II but has encountered delays in late-stage development. Topical imiquimod, a TLR7 agonist approved for other dermatologic conditions, has been studied off-label for CIN 2/3 with inconsistent results and remains unapproved for this use. Cevira thus enters a regulatory pathway with no direct precedent and no approved competitor in the same indication.